In late March 2026, Novavax appointed Dr. Robert Walker as Executive Vice President and Head of R&D, while activist investor Shah Capital renewed its campaign to overhaul the company’s board, ...

Activist investor Shah Capital is renewing its pressure campaign against Novavax (NVAX) as it looks to vote against the re-election of the company’s board nominees and its executive ​compensation ...

Chief among its criticisms is Novavax's failure to build sales of its protein-based COVID-19 vaccine Nuvaxovid/Covovax, a ...

Shah Capital, which has agitated for change at the vaccine maker for years, is calling on fellow shareholders to end what it ...

Wondering whether Novavax at about US$7.98 is a bargain or a value trap? This article walks through the key signals that ...

The Food and Drug Administration authorized Novavax's new protein-based Covid vaccine for emergency use in people ages 12 and up. Novavax's vaccine targets the highly contagious omicron subvariant ...

"Your tenure has overseen a DESTRUCTION of shareholder value—a direct result of chronic operational shortcomings and failures ...

Add Yahoo as a preferred source to see more of our stories on Google. Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other ...

Shah Capital plans “against” votes on directors and say-on-pay, while seeking to sway ISS and Glass Lewis rather than running ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...